A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.
Rachel O. Abelman(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Arielle J. Medford(Harvard University), Philip D. Poorvu(Harvard University), Beverly Moy(Massachusetts General Hospital), Geoffrey Fell(Dana-Farber Cancer Institute), Ana C. Garrido-Castro(Harvard University), Seth A. Wander(Massachusetts General Hospital), Elizabeth A. Mittendorf(Dana-Farber Brigham Cancer Center), Amy Comander(Harvard University), Aditya Bardia(Harvard University), Nadine Tung(Beth Israel Deaconess Medical Center), Leif W. Ellisen(Harvard University), Sara M. Tolaney(Dana-Farber Cancer Institute), Aron S. Rosenstock(Harvard University), Lorenzo Trippa(Harvard University), Filipa Lynce(Georgetown University), Shannon McLaughlin(Harvard University), Steven J. Isakoff(Harvard University)
Cited by 11
Related Papers
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
|Clinical Cancer Research|2016|1.2k
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k